Advertisement

In Singapore, Temasek’s results spark discussion of Chinese investments and Ho Ching

  • Even as it feels the sting of the US-China trade war, the state investment firm is staying true to its strategy of betting big on new trends
  • Its focus on China has mirrored Singapore’s transformation from an export-led economy to one focusing on domestic consumption and services

Reading Time:5 minutes
Why you can trust SCMP
Temasek has invested in BeiGene and Innovent Biologics, which develops therapies and antibodies for diseases such as cancer. Photo: Bloomberg
When Temasek Holdings announced its results early last month, there was no hiding the stark fact that Singapore’s state investment firm was feeling the full effects of the ongoing US-China trade war.
Advertisement

Shareholder returns plunged to 1.49 per cent, down from 12 per cent year on year, and its portfolio value in Singapore dollar terms rose to S$313 billion (US$230.1 billion) as it made divestments of S$28 billion, compared with new investments of S$24 billion.

Beyond these top-line figures, however, Temasek appears to be following its time-tested strategy of betting big on new trends rather than sticking to old economy behemoths.

Overall, just over half of its investments are in financial services; the telecommunications, media and tech sectors; and life sciences and agribusiness. In its investments in China and India, the emphasis has been on tech companies and life sciences.

Chinese investments make up 26 per cent, or S$81.4 billion, of Temasek’s total global portfolio, while Indian investments make up 5 per cent of the total. For the first time, Chinese investments are on par with Singaporean investments.

Advertisement
Advertisement